Cat. No.: HY-N4302

Monensin

(Synonyms: Monensin A)

43 Cited Publications

Customer Review

Based on 43 publication(s) in Google Scholar

Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na⁺/H⁺ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.

For research use only. We do not sell to patients.

Purity: 98.07%
CAS No.: 17090-79-8
Formula: C₃₆H₆₂O₁₁
Molecular Weight:670.87

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Monensin Chemical Structure

CAS No.: 17090-79-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (43)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Antibiotic Isoforms :

All Parasite Isoforms :

All Wnt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BALB/3T3	IC₅₀	20.89 μM Compound: MON	Cytotoxicity against mouse BALB/3T3 cells Cytotoxicity against mouse BALB/3T3 cells	[PMID: 26338363]
Hepatocyte	IC₅₀	<0.001 nM Compound: Monensin	Antimicrobial activity against Plasmodium falciparum NF54 schizonts in mammalian hepatocytes after 96 hrs Antimicrobial activity against Plasmodium falciparum NF54 schizonts in mammalian hepatocytes after 96 hrs	[PMID: 18212104]
Hepatocyte	IC₅₀	<0.001 nM Compound: Monensin	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
LoVo	IC₅₀	1.09 μM Compound: MON	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 26338363]
MV4-11	IC₅₀	0.09 μM Compound: MON	Antiproliferative activity against human MV4-11 cells Antiproliferative activity against human MV4-11 cells	[PMID: 26338363]

In Vitro

Monensin (1-5 μM; 48 h) results in a marked decrease in viability in a dose-dependent manner^[1].
Monensin (1-5 μM; 24 h) shows a statistically significant induction of apoptosis^[1].
Monensin (0.1-1 μM; 24 h) inhibits pEGFR and its downstream targets pAKT and pERK^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SCC9, SCC25, and GM-38 cell lines
Concentration:

1-5 μM
Incubation Time:

48 h
Result:

Resulted in a marked decrease in viability in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:

SCC25 cells
Concentration:

1 μM, or 5 μM
Incubation Time:

24 hours
Result:

Induced a potent apoptotic response.

Western Blot Analysis^[1]

Cell Line:

SCC9 and SCC25 cells
Concentration:

0.1 μM, or 1 μM
Incubation Time:

24 hours
Result:

Induced approximately a 50% inhibition of EGF-treated SCC9 cells with respect to pEGFR and its downstream targets pAKT and pERK.

In Vivo

Monensin (10 mg/kg; po; daily; for 6 weeks) suppresses progression of the intestinal tumors without any sign of toxicity on normal mucosa in multiple intestinal neoplasia (Min) mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Multiple intestinal neoplasia (Min) mice (four-week-old) ^[2]
Dosage:

10 mg/kg
Administration:

Orally application; daily; for 6 weeks
Result:

Suppressed progression of the intestinal tumors without any sign of toxicity on normal mucosa.

Chemical Information

CAS No. 17090-79-8
Appearance Solid
Molecular Weight 670.87
Formula C₃₆H₆₂O₁₁
Color White to light yellow
SMILES

C[C@]1([C@]2([H])O[C@@](CC2)([C@]3([H])O[C@]([C@@]4([H])O[C@](O)([C@@H](C[C@@H]4C)C)CO)([H])C[C@@H]3C)CC)O[C@@]5(CC1)O[C@]([C@@H]([C@H](C5)O)C)([H])[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O
Synonyms

Monensin A
Structure Classification
- Others
Initial Source
- Microorganisms
Streptomyces spp.
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (43)

All Cell Migration/Invasion AssayCell Imaging/StainingWBRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Malate initiates a proton-sensing pathway essential for pH regulation of inflammation. [Abstract]

2024 Dec 30;9(1):367. PMID: 39737965

Monensin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]

Cellular BiP-IRF2BP2 interactions shown by Western blot analysis of co-immunoprecipitation in MG132-pretreated (5 μM, 0.5 h) Raw264.7 cells which were treated with acidized medium (AcM) or with AcM plus Monensin (0.1 μM) in the presence of LPS and MG132 (0.5 μM) for 6 h.

Monensin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]

Il1b expressions in BMDMs isolated from Hspa5^f/f or Hspa5^f/f; Lyz2-Cre mice treated with or without Monensin (1 μM), under stimulation of LPS for 24 h.
Signal Transduct Target Ther

Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. [Abstract]

2023 Jul 17;8(1):273. PMID: 37455272
Nat Methods

SEVtras delineates small extracellular vesicles at droplet resolution from single-cell transcriptomes. [Abstract]

2024 Feb;21(2):259-266. PMID: 38049696
Cell Host Microbe

The intestinal fungus Aspergillus tubingensis promotes polycystic ovary syndrome through a secondary metabolite. [Abstract]

2025 Jan 8;33(1):119-136.e11. PMID: 39788092
Autophagy

High-fat diet exacerbates experimental colitis by inhibiting lysosomal function via the STAT3-TFEB Axis. [Abstract]

2026 May 28:1-24. PMID: 42165414
Autophagy

Trans-Golgi network-associated noncanonical autophagy depends on the V-ATPase-ATG16L1 axis and mediates IL1B secretion. [Abstract]

2025 Dec 8. PMID: 41361996
Nat Commun

ATG8ylation-mediated tonoplast invagination mitigates vacuole damage. [Abstract]

2025 Jul 18;16(1):6621. PMID: 40681515

Monensin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

The impact of different concentrations of monensin on the subcellular localization of YFP-ATG8e. 5-day-old YFP-ATG8e transgenic seedlings were treated with different concentrations of Monensin (5-40 μM; 1 h) in 1/2MS liquid medium, followed by confocal microscopy observation.

Monensin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]

Detection of ROS generation after monensin treatment. 5-day-old mCherry-ATG8f seedlings were subjected to Monensin (20 μM; 1 h) treatment. The ROS-sensitive dye H2DCFDA (1 μM) was incubated 10 min prior to confocal imaging. The images were shown with LUT pseudocolor scale.
Nat Commun

Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. [Abstract]

2025 Mar 10;16(1):2368. PMID: 40064874
Nat Commun

Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice. [Abstract]

2022 Jul 22;13(1):4255. PMID: 35869084
Neuron

CLN3 mediates chloride efflux from lysosomes. [Abstract]

2026 Mar 4;114(5):868-883.e7. PMID: 41558486
Redox Biol

Role of redox-sensitive catalytic interaction with ADAM10 in mutant-selective extracellular shedding of prion protein. [Abstract]

2022 Oct:56:102456. PMID: 36041363
J Nanobiotechnology

Targeting heptad repeats and fusion peptide: nanoparticle vaccine elicits mucosal immune response against SARS-CoV-2 variants. [Abstract]

2025 Jul 3;23(1):483. PMID: 40611257
Theranostics

Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes. [Abstract]

2025 May 25;15(13):6329-6346. PMID: 40521193
J Exp Clin Cancer Res

Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway. [Abstract]

2021 Jan 6;40(1):16. PMID: 33407703
Adv Sci (Weinh)

Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. [Abstract]

2026 May 26:e15158. PMID: 42189126
Cell Death Dis

FTO controls CD8+ T cell survival and effector response by modulating m6A methylation of Fas. [Abstract]

2025 Apr 15;16(1):301. PMID: 40234389
Small

Cell-Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer. [Abstract]

2021 Dec;17(50):e2103984. PMID: 34723421
J Exp Med

Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition. [Abstract]

2023 Mar 6;220(3):e20221316. PMID: 36520461
Adv Healthc Mater

Lipoprotein-Based Nanocatalyst Enables Targeted Treatment of APAP-Induced Liver Injury via Enhanced Macropinocytosis. [Abstract]

2025 May 24:e2500507. PMID: 40411876
Adv Healthc Mater

Self-Assembled Nanoparticles with Well-Defined Oligosaccharide Promote Osteogenesis by Regulating Golgi Stress Response. [Abstract]

2024 Dec 1:e2402976. PMID: 39618007
Acta Pharmacol Sin

Alkalization of the intracellular pH reprograms TNF-α signaling from inflammatory NF-κB activation to tumoricidal RIP kinase-dependent necroptosis in cancer cells. [Abstract]

2026 Apr 8. PMID: 41951772
Proc Natl Acad Sci U S A

Monensin suppresses EMT-driven cancer cell motility by inducing Golgi pH-dependent exocytosis of GOLIM4. [Abstract]

2025 Jul 15;122(28):e2501347122. PMID: 40632561

Monensin purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2501347122. [Abstract]

Boyden chamber transwell assays on mesenchymal NSCLC cells treated with indicated doses of Monensin (100-500 nM; 24 h). Migrated and invaded cells were quantified.
Int J Pharm X

A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport. [Abstract]

2026 May 3:11:100556. PMID: 42110369
Cancer Immunol Res

CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer. [Abstract]

2026 May 4;14(5):875-891. PMID: 41686262
Cell Rep

LAMP2A-mediated neuronal hyperexcitability by enhancing NKAβ1 degradation underlies depression-induced allodynia. [Abstract]

2025 Apr 2;44(4):115489. PMID: 40178973
Talanta

Fluorescence-activated cell sorting-based efficient screening of monensin monoclonal antibodies and applications in lateral flow immunoassay. [Abstract]

2025 Apr 10:293:128128. PMID: 40222095
Biochem Pharmacol

Repurposing TAK875 as a novel STAT3 inhibitor for treating inflammatory bowel disease. [Abstract]

2024 Jan:219:115957. PMID: 38049007
Oncoimmunology

CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport. [Abstract]

2023 Apr 19;12(1):2204015. PMID: 37089447
Front Microbiol

Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. [Abstract]

2020 Apr 30;11:790. PMID: 32425913
Int Immunopharmacol

Tespa1 deficiency reduces the antitumour immune response by decreasing CD8+T cell activity in a mouse Lewis lung cancer model. [Abstract]

2023 Sep 1;124(Pt A):110865. PMID: 37660596
AAPS PharmSciTech

Transcellular Transport Behavior of the Intact Polymeric Mixed Micelles with Different Polymeric Ratios. [Abstract]

2023 Feb 15;24(2):69. PMID: 36792796
Sci Rep

ARL8B regulates lysosomal function and predicts poor prognosis in hepatocellular carcinoma. [Abstract]

2025 Apr 10;15(1):12278. PMID: 40210693
Eur J Med Res

Invisible appliance promotes bone reconstruction via modulating the periodontal immune microenvironment. [Abstract]

2025 May 12;30(1):378. PMID: 40350478
J Inflamm Res

Interleukin-27 and Interleukin-2 Cooperatively Regulate CD4⁺ T Cell Subsets and Immune Imbalance in Coronary Artery Disease. [Abstract]

2025 Dec 10:18:17253-17269. PMID: 41399529
Clin Immunol

The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway. [Abstract]

2023 Mar:248:109217. PMID: 36581220
Clin Exp Immunol

FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response. [Abstract]

2024 Mar 12;216(1):68-79. PMID: 38146642
Exp Cell Res

Septins regulate kinase-inhibitor induced micron-scale vacuolation. [Abstract]

2026 Aug 1;461(1):115103. PMID: 42276196
Int J Parasitol Drugs Drug Resist

Forward genetic analysis of monensin and diclazuril resistance in Eimeria tenella. [Abstract]

2023 Aug:22:44-51. PMID: 37247559
SSRN

2025 Sep 30.
bioRxiv

Interpretable representation learning for 3D multi-piece intracellular structures using point clouds. [Abstract]

2024 Jul 27:2024.07.25.605164. PMID: 39091871
bioRxiv

Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma. [Abstract]

2023 Sep 12:2023.09.09.557001. PMID: 37745469
Research Square Preprint

2023 Aug 31.
bioRxiv

2023 Jun 25.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (149.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4906 mL

7.4530 mL

14.9060 mL

5 mM

0.2981 mL

1.4906 mL

2.9812 mL

10 mM

0.1491 mL

0.7453 mL

1.4906 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71. [Content Brief]

[2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22. [Content Brief]

[3]. Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. [Content Brief]

[4]. Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4906 mL	7.4530 mL	14.9060 mL	37.2650 mL
	5 mM	0.2981 mL	1.4906 mL	2.9812 mL	7.4530 mL
	10 mM	0.1491 mL	0.7453 mL	1.4906 mL	3.7265 mL
	15 mM	0.0994 mL	0.4969 mL	0.9937 mL	2.4843 mL
	20 mM	0.0745 mL	0.3727 mL	0.7453 mL	1.8633 mL
	25 mM	0.0596 mL	0.2981 mL	0.5962 mL	1.4906 mL
	30 mM	0.0497 mL	0.2484 mL	0.4969 mL	1.2422 mL
	40 mM	0.0373 mL	0.1863 mL	0.3727 mL	0.9316 mL
	50 mM	0.0298 mL	0.1491 mL	0.2981 mL	0.7453 mL
	60 mM	0.0248 mL	0.1242 mL	0.2484 mL	0.6211 mL
	80 mM	0.0186 mL	0.0932 mL	0.1863 mL	0.4658 mL
	100 mM	0.0149 mL	0.0745 mL	0.1491 mL	0.3727 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Monensin

Anti-Infection Compound Library

Apoptosis Compound Library

Membrane Transporter/Ion Channel Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Antifungal Compound Library

Antibacterial Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Antibiotics Library

Neuroprotective Compound Library

Exosomes Compound Library

Anti-Breast Cancer Compound Library

Antiparasitic Compound library

Microbial Metabolite Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Animal Drug Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Monensin

All Antibiotic Isoforms

All Parasite Isoforms

All Wnt Isoforms

Biological Activity

Chemical Information

Publications (43)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Monensin Related Classifications

HY-N4302 Related Classifications